Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol (VITAKET)

Technische Universität Dresden

Status and phase: Unknown; Phase 2

Conditions: Psoriasis Vulgaris

Treatments: Radiation: UVB-radiation 311nm; Drug: Ketokonazol 2% cream

Study type: Interventional

Funder types: Other

Identifiers

NCT00678756

TUD-VITAKET

Details and patient eligibility

About

Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

Enrollment: 12 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age: 18- 80
• diagnosis of psoriasis vulgaris (mild- middle)
• no other current antipsoriatic therapy (systemic/topical)
• at least 5 psoriatic areas of 5x5 cm

Exclusion criteria

• pregnancy/nursing mothers
• women in reproductive age without adequate contraception
• severe and acute forms of psoriasis vulgaris
• patients receiving systemic or topical antipsoroatic treatment in past 3 month
• UV-therapy in past 3 month
• patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma
• epilepsy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)